Research programme: radiolabelled PSMA antibody therapeutics - Cytogen
Alternative Names: LU-177-7E11; Lutetium-177-labelled 7E11 monoclonal antibody; Lutetium-177-labelled PSMA antibody; Research programme: radiolabelled 7E11 antibody - Cytogen; Research programme: radionuclide-labelled PSMA antibody - CytogenLatest Information Update: 04 Nov 2017
At a glance
- Originator Cytogen Corporation; Dow Chemical
- Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Angiogenesis inhibitors; Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Prostate cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Prostate-cancer in USA (Parenteral)
- 31 Dec 2007 This collaboration is still active